Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Mok et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69d7485a58d71cbec648f643 — DOI: https://doi.org/10.1200/jco.23.01017

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey· 2014 · 186 citations
2. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer· 2017 · 2,566 citations
3. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer· 2019 · 2,819 citations
4. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors· 2019 · 963 citations
5. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain· 2021 · 295 citations